CN107233303A - A kind of aminolevulinic acid cold cream and its preparation method and application - Google Patents
A kind of aminolevulinic acid cold cream and its preparation method and application Download PDFInfo
- Publication number
- CN107233303A CN107233303A CN201710666915.XA CN201710666915A CN107233303A CN 107233303 A CN107233303 A CN 107233303A CN 201710666915 A CN201710666915 A CN 201710666915A CN 107233303 A CN107233303 A CN 107233303A
- Authority
- CN
- China
- Prior art keywords
- aminolevulinic acid
- cold cream
- acid cold
- emulsion
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0061—5-aminolevulinic acid-based PDT: 5-ALA-PDT involving porphyrins or precursors of protoporphyrins generated in vivo from 5-ALA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/06—Emulsions
- A61K8/064—Water-in-oil emulsions, e.g. Water-in-silicone emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/81—Preparation or application process involves irradiation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Birds (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Biochemistry (AREA)
- Cosmetics (AREA)
Abstract
The invention discloses a kind of aminolevulinic acid cold cream, it includes acceptable auxiliary material in aminolevulinic acid derivative, emulsion and other pharmacies or cosmetics；Wherein, the emulsion includes at least one aqueous components, at least one alcohol and at least one surfactant.Present invention also offers the preparation method of above-mentioned aminolevulinic acid cold cream and its application in medicine and cosmetics.The aminolevulinic acid cold cream of the present invention; in dept. of dermatology field; main function is the local treatment to skin, protects damaged part not contacted with the external world, it is possible to increase drugloading rate and bioavilability; it is easy to use; skin sense is comfortable, and composition is uniform, and chemical property is stable; ALA permeability can be improved, and then strengthens the permeability of skin and tissue；Technically it is easier to promote.
Description
Technical field
The present invention relates to a kind of aminolevulinic acid cold cream and its preparation method and application, belong to technical field of pharmaceuticals.
Background technology
5-ALA (ALA) is a kind of photosensitive drug, and treatment can be played with reference to the illumination of appropriate energy and wavelength
Effect, ALA photodynamic therapies have been widely used in dermatological field at present, and its technical merit is also constantly being opened up.
The treatment basis of photodynamic therapy (Photodynamic therapy, PDT) is：Body is first given to tumor tissues
The sensitising agent of selective intake effect, then with specific wavelength laser irradiation tumor tissues, the photochemistry for inducing sensitising agent is anti-
Activity very strong singlet oxygen should be generated, and then occurs oxidation reaction with large biological molecule, CDCC is produced swollen to kill
Oncocyte and show therapeutic action.Compared with the tumour traditional remedies such as operation, radiotherapy, chemotherapy and immunization therapy, photodynamics is controlled
It is that can carry out selective destruction to cancerous tissue to treat biggest advantage, and side effect is smaller.
5-ALA (5-aminolevulinic acid, ALA) is as second generation Porphyrin-Based Sensitizer, gradually
As clinical the most frequently used sensitising agent.ALA is a kind of endogenic optical dynamic therapy medicine, is animal ferroheme and plant leaf green
The precursor substance of plain biosynthesis, itself and unglazed toxic action.Under normal circumstances, the content that body passes through intracellular ferroheme
Negative feedback inhibition ALA synzyme, controls ALA growing amount, so being accumulated in vivo without excessive ALA.But a large amount of exogenous ALA
Into after in vivo, it can be absorbed by tumour cell and the vigorous cell selective of other hyperplasia, the tool for making intracellular accumulation excessive
There is strong photosensitive material protoporphysin Ⅸ (Pp Ⅸ), Pp Ⅸ can chemically react under the irradiation of certain wavelength, produce a large amount of
Active oxygen (ROS) and free radical, cause the damage of cell membrane, mitochondria and nucleic acid, make meronecrosis or apoptosis, are controlled so as to reach
Treat the effect of disease.ALA is small-molecule substance, can local application, without special after no obvious adverse reaction, and topical application ALA
Different lucifuge, because protoporphysin Ⅸ has been degraded or has been quenched after red light irradiation.Because ALA-PDT has, adverse reaction is small, curative effect
Definite the advantages of, the treatment of tumour, precancerous lesion and some Non-cancerous disease of skin is widely used to, its therapeutic domain is
Expand to that the skins such as basal-cell carcinoma, squamous cell carcinoma, bowen's disease, solar keratosis, condyloma acuminatum are benign and neoplasm
Property disease.Meanwhile, ALA-PDT also has more application in terms of beauty, the tender skin of light, cosmetics.Multinomial research has shown that PDT is treated
Method can repair the damaged skin of light aging, wherein, the photodynamic therapy effect with reference to ALA is more notable, can effectively improve skin
The skin problems such as skin relaxation, wrinkle, pigmentation, chloasma, pachylosis, telangiectasis.
However, ALA photodynamic therapies also have certain limitation.Because ALA is polar compound, percutaneous permeability compared with
It is low, it is difficult to reach the damaged part of skin histology.Current China is generally adopted by higher concentration 20% on clinical treatment
ALA solution, needs the aminolevulinic acid normal saline solution of Fresh when using, dropped in rayon balls and then be covered in
Need the region for the treatment of.This method is inconvenient for use, and drug distribution is uneven, and bioavilability is low.Also, due to drug concentration
Too high, the patient more than half can produce phototoxic side effect.In order to improve ALA clinical effectiveness, it would be highly desirable to the problem of solving
Raising ALA permeability is how, the permeability of its consumption, enhancing skin and tissue is reduced.
Cold cream, also referred to as face cream or face cream, are a kind of oil-in-water creams, are applied on skin and have moisture separation
Out, moisture evaporation takes away the heat of skin, skin is had refrigerant sensation, so referred to as cold cream.In cold cream oil phase into
Divide content higher, it is in solid that not only can effectively pin under moisture of skin, and cold cream normal temperature, be also beneficial to improve amino ketones
The storage stability of valeric acid.
The content of the invention
In view of the defect that above-mentioned prior art is present, can the purpose of the present invention is to propose to a kind of aminolevulinic acid cold cream
Drugloading rate and bioavilability are improved, convenient use improves ALA permeability, and then strengthen the permeability of skin and tissue.
The purpose of the present invention is achieved by the following technical programs：
A kind of aminolevulinic acid cold cream, it includes aminolevulinic acid derivative, emulsion and other pharmacies or cosmetics
In acceptable auxiliary material；
Counted using the gross weight of emulsion as 100%, the content of the aqueous components is 50%-98%, the content of the alcohol
For 1%-10%, the content of the surfactant is 0.1%-5%.
In above-mentioned aminolevulinic acid cold cream, pharmacy or the acceptable auxiliary material of cosmetic field include but is not limited to list firmly
Glycerol, preservative, albolene, white oil, beeswax, lanolin, glycerine, water, salicylic acid etc..
In above-mentioned aminolevulinic acid cold cream, emulsion include at least one aqueous components and carrier (at least one alcohol, extremely
A kind of few surfactant), wherein aqueous components are mainly to form buffer salt system.
In above-mentioned aminolevulinic acid cold cream, it is preferred that the aminolevulinic acid cold cream includes the following raw material component：
In above-mentioned aminolevulinic acid cold cream, it is preferred that the aminolevulinic acid derivative includes MAL
One or more of combinations in hydrochloride, aminolevulinic acid phosphate and aminovaleric acid hydrochloride.
In above-mentioned aminolevulinic acid cold cream, it is preferred that the aminolevulinic acid cold cream includes the following raw material component：
In above-mentioned aminolevulinic acid cold cream, it is preferred that the monostearate that the emulsifying agent includes 270-330 parts by weight is sweet
The Tween 80 of grease and 15-20 parts by weight.
In above-mentioned aminolevulinic acid cold cream, it is preferred that the aminolevulinic acid cold cream includes the following raw material component：
In above-mentioned aminolevulinic acid cold cream, it is preferred that the emulsifying agent includes the glycerin monostearate of 319 parts by weight
With the Tween 80 of 19 parts by weight.
In above-mentioned aminolevulinic acid cold cream, it is preferred that the alcohol includes isopropanol.
In above-mentioned aminolevulinic acid cold cream, it is preferred that the aqueous components include phosphate buffer.
In above-mentioned aminolevulinic acid cold cream, surfactant is used for film forming, can select phosphatide or ceramide；It is preferred that
, the surfactant includes lecithin.
In above-mentioned aminolevulinic acid cold cream, lecithin is preferably soybean lecithin or egg lecithin；It is preferred that, it is described
Surfactant is soybean lecithin.
The aminolevulinic acid cold cream of the present invention is a kind of reagent of water in oil form, and this composition causes the stability of medicine
It is improved.Isopropanol rather than ethanol are selected, is due to that isopropanol may be such that the yardstick of particulate in uniform emulsion is smaller, particle
Reduce the stability for being conducive to improving reagent.
In above-mentioned aminolevulinic acid cold cream, it is preferred that in the emulsion described in per unit, include 2g soybean lecithin
The phosphate buffer of fat, 6g isopropanol and 90mL.
In above-mentioned aminolevulinic acid cold cream, phosphate buffer is common agents, can be made by conventional method, side
Method is as follows：Sodium dihydrogen phosphate 3g is taken, is dissolved in 100ml water, obtains sodium dihydrogen phosphate；Disodium hydrogen phosphate 1g is taken, 20ml is dissolved in
In water, disodium phosphate soln is obtained；Take sodium dihydrogen phosphate 85ml and disodium phosphate soln 15ml respectively again, mixing is mixed
It is even, adjust pH value to 6, produce phosphate buffer solution.
The present invention also provides the preparation method of above-mentioned aminolevulinic acid cold cream, comprises the following steps：
Obtain carrying medicine phases after aminolevulinic acid derivative is mixed with emulsion；
Albolene, white oil, lanolin, beeswax are mixed with emulsifying agent, heat is standby to 70 DEG C of -80 DEG C of insulations altogether, during which
It is stirred continuously, obtains oil phase；
Water and glycerine are mixed, addition bigcatkin willow acid for adjusting pH value is about 6, and heat is standby to 70 DEG C of -80 DEG C of insulations altogether, obtains water
Phase；
Under 70 DEG C of -80 DEG C of water bath conditions, aqueous phase is slowly added into oil phase, adition process and is stirred continuously；(preferably 5min
The mixture stirred is removed into water bath afterwards), natural cooling, when mixture temperature is down to 50 DEG C, adds and carries medicine phases,
Room temperature is cooled to after stirring, aminolevulinic acid cold cream is obtained.
In above-mentioned preparation method, it is preferred that the emulsion is by being fallen after soybean lecithin is mixed with isopropanol
Enter in phosphate buffer, be mixed to get.
In above-mentioned preparation method, it is preferred that the emulsifying agent is by the way that glycerin monostearate and Tween 80 are mixed
Prepare.
The present invention also provides a kind of composition, and it includes above-mentioned aminolevulinic acid cold cream.
In combinations of the above thing, in cosmetic field, for the different purposes of final products, the examination of non-therapeutic can be added
Agent, such as：Emollient, colouring agent, spices etc., for the purpose of local beauty, it should be noted that avoid hindering the transparency of product.
The present invention also provides above-mentioned aminolevulinic acid cold cream is including condyloma acuminatum, solar lentigines angling as preparation treatment
Application in the dermopathic medicine of disease and squamous cell carcinoma.
The present invention also provides application of the above-mentioned aminolevulinic acid cold cream in as cosmetics and skincare product or cosmetics.It can use
In the tender skin of light, whitening, improve freckle, microgroove, the light aging problem such as pachylosis, it is good and cold cream is in faintly acid using comfort,
The acid-base value of suitable skin.
The present invention protrusion effect be：
The aminolevulinic acid cold cream of the present invention, in dept. of dermatology field, main function is the local treatment to skin, protection by
Damage position not contact with the external world, it is possible to increase drugloading rate and bioavilability, easy to use, skin sense is comfortable, and composition is uniform, chemistry
Property is stable, it is possible to increase ALA permeability, and then strengthens the permeability of skin and tissue；Technically it is easier to promote.
Embodiment
The technical scheme in the present invention is clearly and completely described below in conjunction with specific embodiment, it is clear that retouched
The embodiment stated is only a part of embodiment of the invention, rather than whole embodiments.Based on the embodiment in the present invention, sheet
The every other embodiment that field those of ordinary skill is obtained under the premise of creative work is not made, belongs to the present invention
The scope of protection.
Embodiment 1
The present embodiment provides a kind of aminolevulinic acid cold cream (10wt% aminolevulinic acid contents cold cream), and it includes following original
Expect component：
MAL hydrochloride 0.5g, glycerin monostearate 0.33g, Tween 80 0.019g, albolene
0.39g, white oil 1.36g, lanolin 0.16g, beeswax 0.23g, salicylic acid 0.01g (are used to adjust pH), glycerine 0.2g, water
1.2g, uniform emulsion 0.62g.
The preparation method of the MAL hydrochloride cold cream of the present embodiment is as follows：
Step 1：Prepare emulsion：Soybean lecithin 2g is taken in centrifuge tube, 6g isopropanols are added；Vibration is well mixed；
Mixture is slowly added into 90ml phosphate buffers, is well mixed, produces；
Above-mentioned phosphate buffer solution is to be prepared via a method which：Sodium dihydrogen phosphate 3g is taken, is dissolved in 100ml water,
Obtain sodium dihydrogen phosphate；Disodium hydrogen phosphate 1g is taken, is dissolved in 20ml water, obtains disodium phosphate soln；Take di(2-ethylhexyl)phosphate respectively again
Hydrogen sodium solution 85ml and disodium phosphate soln 15ml, mixing is mixed, and regulation pH value produces phosphate buffer solution to 6；
Step 2：Prepare and carry medicine phases：MAL hydrochloride is weighed, emulsion is added, vibration is well mixed, i.e.,
；
Step 3：Prepare oil phase：Albolene, white oil, lanolin, beeswax are weighed, emulsifying agent (glycerol monostearate is added
Ester and Tween 80, which are mixed with, to be obtained), mixing is hot standby to 75 DEG C of insulations altogether by oil phase and emulsifying agent, is during which stirred continuously；
Step 4：Prepare aqueous phase：By water and glycerine by mixing, a certain amount of salicylic acid is added, is about 6 for adjusting pH, altogether
Heat is incubated standby to 70-80 DEG C；
Step 5：Under 70-80 DEG C of water bath condition, aqueous phase is slowly added into oil phase, adition process using dropper and uses magnetic
Power agitator is stirred continuously, and speed is about 1300r/min, obtains mixture；
Step 6：When the temperature of mixture in step 5 is cooled down into 50 DEG C, load medicine phases are slowly added into using dropper, are stirred
Room temperature is cooled to after uniform, that is, obtains aminolevulinic acid cold cream.
Embodiment 2
The present embodiment provides a kind of MAL hydrochloride cold cream (16% aminolevulinic acid content cold cream), and it is wrapped
Include the following raw material component：
MAL hydrochloride 0.8g, glycerin monostearate 0.27g, Tween 80 0.016g, albolene
0.32g, white oil 1.12g, lanolin 0.13g, beeswax 0.19g, salicylic acid 0.01g (are used to adjust pH), glycerine 0.16g, water
1.0g, uniform emulsion 1.0g.
The preparation method of the MAL hydrochloride cold cream of the present embodiment is as follows：
Step 1：Prepare emulsion：Soybean lecithin 2g is taken in centrifuge tube, 6g isopropanols are added；Vibration is well mixed；
Mixture is slowly added into 90ml phosphate buffers, is well mixed, produces；
Above-mentioned phosphate buffer solution is to be prepared via a method which：Sodium dihydrogen phosphate 3g is taken, is dissolved in 100ml water, obtains
Sodium dihydrogen phosphate；Disodium hydrogen phosphate 1g is taken, is dissolved in 20ml water, obtains disodium phosphate soln；Take biphosphate respectively again
Sodium solution 85ml and disodium phosphate soln 15ml, mixing is mixed, and regulation pH value produces phosphate buffer solution to 6；
Step 2：Prepare and carry medicine phases：Weigh MAL hydrochloride appropriate, add appropriate uniform emulsion, vibration
It is well mixed；
Step 3：Prepare oil phase：Albolene, white oil, lanolin, beeswax are weighed, emulsifying agent (glycerol monostearate is added
Ester and Tween 80, which are mixed with, to be obtained), mixing is hot standby to 75 DEG C of insulations altogether by oil phase and emulsifying agent, is during which stirred continuously；
Step 4：Prepare aqueous phase：By water and glycerine by mixing, a certain amount of salicylic acid is added, is about 6 for adjusting pH, will
Heat, to 70-80 DEG C, is incubated standby aqueous phase altogether；
Step 5：Under 70-80 DEG C of water bath condition, aqueous phase is slowly added into oil phase, adition process using dropper and uses magnetic
Power agitator is stirred continuously, and speed is about 1300r/min, obtains mixture；
Step 6：When the temperature of mixture in step 5 is cooled down into 50 DEG C, load medicine phases are slowly added into using dropper, are stirred
Room temperature is cooled to after uniform, that is, obtains aminolevulinic acid cold cream.
Embodiment 3
The present embodiment provides a kind of aminolevulinic acid cold cream (20% aminolevulinic acid content cold cream), and it includes the following raw material
Component：
MAL hydrochloride 1g, glycerin monostearate 0.032g, Tween 80 0.019g, albolene
0.37g, white oil 1.13g, lanolin 0.15g, beeswax 0.23g, salicylic acid 0.01g (it is about 6 to be used to adjust pH value), glycerine
0.19g, water 1.12g, uniform emulsion 1.25g.
The preparation method process be the same as Example 1,2 of the MAL hydrochloride cold cream of the present embodiment.
Embodiment 4
The present embodiment provides a kind of aminolevulinic acid cold cream, and it includes the following raw material component：
Aminolevulinic acid phosphate 1g, glycerin monostearate 0.032g, Tween 80 0.019g, albolene 0.37g,
White oil 1.13g, lanolin 0.15g, beeswax 0.23g, salicylic acid 0.01g (it is about 6 to be used to adjust pH value), glycerine 0.19g, water
1.12g, uniform emulsion 1.25g.
The preparation method process be the same as Example 1,2 of the MAL hydrochloride cold cream of the present embodiment.
Embodiment 5
The present embodiment provides a kind of aminolevulinic acid cold cream, and it includes the following raw material component：
Aminovaleric acid hydrochloride 1g, glycerin monostearate 0.032g, Tween 80 0.019g, albolene 0.37g,
White oil 1.13g, lanolin 0.15g, beeswax 0.23g, salicylic acid 0.01g (it is about 6 to be used to adjust pH value), glycerine 0.19g, water
1.12g, uniform emulsion 1.25g.
The preparation method process be the same as Example 1,2 of the MAL hydrochloride cold cream of the present embodiment.
Embodiment 6
The present embodiment provides a kind of aminolevulinic acid cold cream, and it includes the following raw material component：
MAL hydrochloride and aminovaleric acid hydrochloride are (according to 2:1 weight is than mixing) 1g, it is single stearic
Acid glyceride 0.032g, Tween 80 0.019g, albolene 0.37g, white oil 1.13g, lanolin 0.15g, beeswax 0.23g, water
Poplar acid 0.01g (it is about 6 to be used to adjust pH value), glycerine 0.19g, water 1.12g, uniform emulsion 1.25g.
The preparation method process be the same as Example 1,2 of the MAL hydrochloride cold cream of the present embodiment.
Embodiment 7
The present embodiment provides a kind of clinical practice of aminolevulinic acid cold cream, the amino ketones penta for verifying embodiment 1-3
The action effect of sour cold cream：
Randomly select 20 suffer from skin problem patients, be randomly divided into 3 groups, respectively using 10%, 16%, 20% this three
The aminolevulinic acid cold cream of various concentrations is planted, coordinates photodynamic therapy, external curing skin problem carries out comparative study, observation
The curative effect of various concentrations and its adverse reaction.Treatment method is：Medication once, after coating 2h, is cleaned, then shone with feux rouges weekly
Penetrate, irradiation time, irradiation gross energy about 100J/cm are adjusted according to irradiated area2, medicine is shared three times, after each course for the treatment of terminates
Follow-up is carried out, therapeutic effect is tracked in time.
1st, skin whitening, moisturizing effect expedition
The moisturizing effect of cold cream made from embodiment 1-3 is evaluated using the cutaneous sensibility of human body.Subject is every
After secondary use, used cold cream is given a mark.The total score of every using effect is 5 points, 5 points to be very satisfied, 4 points be compared with
Satisfied, 3 points are to receive, and 2 points are bad, and 1 point is very poor.It is below every average, is shown in Table 1.
The skin whitening, moisturizing effect expedition of the aminolevulinic acid cold cream of table 1 embodiment 1-3, tri- kinds of different contents
| Whitening | Moistness | |
| 10% aminolevulinic acid cold cream | 4.2 | 4.6 |
| 16% aminolevulinic acid cold cream | 4.6 | 4.8 |
| 20% aminolevulinic acid cold cream | 4.7 | 4.6 |
As a result show, whitening and moisturizing effect of the subject to the aminolevulinic acid cold cream of the present invention are had higher rating.
2nd, clinical therapeutic efficacy
Criterion of therapeutical effect：Recovery from illness：Erythema comedo disappears, and recovers normal skin tone.It is evident in efficacy：Erythema comedo disappear it is most of or
It has been reduced that, the damaged skin for crossing semi-area recovers normal skin tone.Effectively：Erythema comedo has taken a turn for the better, and recovers normal skin
Area is more than 10.It is invalid：Erythema comedo is unchanged, recovers normal skin area and is less than 10.Recovery from illness, curative effect
Significantly, effective three combine and calculate as effective percentage.Therapeutic effect is shown：Most patients after the treatment of three courses for the treatment of,
Skin of face problem has taken a turn for the better, and has indivedual skin problems more serious patient after second is treated, the increase of erythema area,
Acne increase, continues medication, has alleviated after being treated at three times, by bimestrial convalescence after treatment, the big portion of skin problem
Divide and recover normal.Specific curative effect see the table below：
The clinical effectiveness of the aminolevulinic acid cold cream of table 2 embodiment 1-3, tri- kinds of different contents
| Number of cases | Recovery from illness | It is evident in efficacy | Effectively | It is invalid | It is efficient | |
| 10% aminolevulinic acid cold cream | 7 | 1 | 2 | 2 | 2 | 71.43% |
| 16% aminolevulinic acid cold cream | 6 | 1 | 3 | 1 | 1 | 83.33% |
| 20% aminolevulinic acid cold cream | 7 | 2 | 3 | 1 | 1 | 85.71% |
It can be seen that, the raising of drugloading rate can improve the clinical effectiveness of aminolevulinic acid cold cream, meanwhile, the amino ketones of high concentration
Valeric acid cold cream, which also has, preferably moistens degree, and skin experience sense is preferable.
That is, above-described embodiment is visible, aminolevulinic acid cold cream of the invention, in dept. of dermatology field, main function
For the local treatment to skin, damaged part is protected not contacted with the external world, it is possible to increase drugloading rate and bioavilability, user
Just, comfortably, composition is uniform for skin sense, and chemical property is stable, it is possible to increase ALA permeability, and then strengthens skin and oozing for organizing
Permeability；Technically it is easier to promote.
The foregoing description of the disclosed embodiments, enables professional and technical personnel in the field to realize or using the present invention.
A variety of modifications to these embodiments will be apparent for those skilled in the art, as defined herein
General Principle can be realized in other embodiments without departing from the spirit or scope of the present invention.Therefore, it is of the invention
The embodiments shown herein is not intended to be limited to, and is to fit to and principles disclosed herein and features of novelty phase one
The most wide scope caused.
Claims (13)
1. a kind of aminolevulinic acid cold cream, it is included in aminolevulinic acid derivative, emulsion and other pharmacies or cosmetics
Acceptable auxiliary material；
Wherein, the emulsion includes at least one aqueous components, at least one alcohol and at least one surfactant；
Counted using the gross weight of emulsion as 100%, the content of the aqueous components is 50%-98%, and the content of the alcohol is
1%-10%, the content of the surfactant is 0.1%-5%.
2. aminolevulinic acid cold cream according to claim 1, wherein, the aminolevulinic acid cold cream includes the following raw material group
Point：
3. aminolevulinic acid cold cream according to claim 2, wherein, the aminolevulinic acid derivative includes amino ketones penta
One or more of combinations in acid methyl ester hydrochloride salt, aminolevulinic acid phosphate and aminovaleric acid hydrochloride.
4. aminolevulinic acid cold cream according to claim 3, wherein, the aminolevulinic acid cold cream includes the following raw material group
Point：
5. the aminolevulinic acid cold cream according to claim any one of 2-4, wherein, the emulsifying agent includes 270-330 weights
Measure the glycerin monostearate of part and the Tween 80 of 15-20 parts by weight.
6. aminolevulinic acid cold cream according to claim 4, wherein, the aminolevulinic acid cold cream includes the following raw material group
Point：
It is preferred that, the emulsifying agent includes the glycerin monostearate of 319 parts by weight and the Tween 80 of 19 parts by weight.
7. the aminolevulinic acid cold cream according to claim any one of 1-6, wherein, the alcohol includes isopropanol；It is preferred that,
The aqueous components include phosphate buffer；It is preferred that, the surfactant includes lecithin；It is further preferred that institute
Surfactant is stated for soybean lecithin.
8. aminolevulinic acid cold cream according to claim 7, wherein, in the emulsion described in per unit, including 2g's is big
The phosphate buffer of beans lecithin, 6g isopropanol and 90mL.
9. the preparation method of the aminolevulinic acid cold cream described in claim any one of 1-8, comprises the following steps：
Obtain carrying medicine phases after aminolevulinic acid derivative is mixed with emulsion；
Albolene, white oil, lanolin, beeswax are mixed with emulsifying agent, heat is standby to 70 DEG C of -80 DEG C of insulations altogether, obtains oil phase；
Water and glycerine are mixed, addition bigcatkin willow acid for adjusting pH value is 6, and heat is standby to 70 DEG C of -80 DEG C of insulations altogether, obtains aqueous phase；
Under 70 DEG C of -80 DEG C of water bath conditions, aqueous phase is added and is stirred continuously in oil phase, adition process；By the mixture after stirring
Water bath is removed, cooling, when mixture temperature is down to 50 DEG C, adds and carries medicine phases, be cooled to room temperature after stirring, obtain amino
Ketone valeric acid cold cream.
10. preparation method according to claim 9, wherein, the emulsion is by by soybean lecithin and isopropanol
Pour into phosphate buffer, be mixed to get after mixing.
11. preparation method according to claim 9, wherein, the emulsifying agent is by by glycerin monostearate and telling
Temperature 80 is mixed with what is obtained.
12. aminolevulinic acid cold cream described in claim any one of 1-8 as prepare treatment include condyloma acuminatum, it is solar lentigines
Application in the dermopathic medicine of keratosis and squamous cell carcinoma.
13. application of the aminolevulinic acid cold cream described in claim any one of 1-8 in as cosmetics and skincare product or cosmetics.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710666915.XA CN107233303A (en) | 2017-08-07 | 2017-08-07 | A kind of aminolevulinic acid cold cream and its preparation method and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710666915.XA CN107233303A (en) | 2017-08-07 | 2017-08-07 | A kind of aminolevulinic acid cold cream and its preparation method and application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107233303A true CN107233303A (en) | 2017-10-10 |
Family
ID=59988519
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710666915.XA Pending CN107233303A (en) | 2017-08-07 | 2017-08-07 | A kind of aminolevulinic acid cold cream and its preparation method and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107233303A (en) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000028971A1 (en) * | 1998-11-12 | 2000-05-25 | Asat Ag Applied Science & Technology | Nano-emulsion of 5-aminolevulinic acid |
| DE19832221C2 (en) * | 1998-07-17 | 2000-07-27 | Manfred Neubauer | Method and device for cosmetic hair removal |
| WO2000071089A1 (en) * | 1999-05-19 | 2000-11-30 | Commonwealth Scientific And Industrial Research Organisation | Control of wool growth in sheep and related animals |
| CN101588792A (en) * | 2006-12-22 | 2009-11-25 | 生物前沿生物科学有限公司 | Nano-emulsion |
| CN105708788A (en) * | 2016-02-24 | 2016-06-29 | 济南梵康医疗科技有限公司 | Method for preparing hydrochloric aminolevulinic acid nano emulsifiable paste |
| CN105916498A (en) * | 2013-12-20 | 2016-08-31 | 盖尔德马研究及发展公司 | Pulse photodynamic treatment of acne |
| CN106074203A (en) * | 2016-08-29 | 2016-11-09 | 李金华 | A kind of light speckles, beautification and white frost and preparation method thereof |
-
2017
- 2017-08-07 CN CN201710666915.XA patent/CN107233303A/en active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19832221C2 (en) * | 1998-07-17 | 2000-07-27 | Manfred Neubauer | Method and device for cosmetic hair removal |
| WO2000028971A1 (en) * | 1998-11-12 | 2000-05-25 | Asat Ag Applied Science & Technology | Nano-emulsion of 5-aminolevulinic acid |
| US6559183B1 (en) * | 1998-11-12 | 2003-05-06 | Asat Ag Applied Science & Technology | Nano-emulsion of 5-aminolevulinic acid |
| WO2000071089A1 (en) * | 1999-05-19 | 2000-11-30 | Commonwealth Scientific And Industrial Research Organisation | Control of wool growth in sheep and related animals |
| CN101588792A (en) * | 2006-12-22 | 2009-11-25 | 生物前沿生物科学有限公司 | Nano-emulsion |
| CN105916498A (en) * | 2013-12-20 | 2016-08-31 | 盖尔德马研究及发展公司 | Pulse photodynamic treatment of acne |
| CN105708788A (en) * | 2016-02-24 | 2016-06-29 | 济南梵康医疗科技有限公司 | Method for preparing hydrochloric aminolevulinic acid nano emulsifiable paste |
| CN106074203A (en) * | 2016-08-29 | 2016-11-09 | 李金华 | A kind of light speckles, beautification and white frost and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 崔结等编著: "《日用化学知识与技术》", 30 November 1994, 兵器工业出版社 * |
| 胡玉兰等主编: "《医院外用制剂研究》", 30 November 2004, 中国科学技术出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100475189C (en) | Cosmetics composition, preparing method and use thereof | |
| CN101869539B (en) | Desensitizing composite nano emulsion for sensitive skin repair and preparation method thereof | |
| WO2014188276A2 (en) | Antioxidant compositions and methods of using the same | |
| JP4615671B2 (en) | Preventing wrinkle formation or loss of skin elasticity for use in the presence of inflammation | |
| WO2012112796A2 (en) | Perfluoro(n-butylcyclohexane) compositions and uses thereof | |
| CN101322750B (en) | Novel use of Cistanche tubulosa extract | |
| CN110325246B (en) | Sunscreen composition | |
| CN105687059A (en) | Cosmetic composition for relieving senescence, as well as preparation method and application thereof | |
| US20050137164A1 (en) | Diclofenac compositions for the treatment of skin disorders | |
| CN112587446A (en) | Composition for treating acne and preparation method and application thereof | |
| US20190269738A1 (en) | Camelid compound(s), composition(s) and method(s) | |
| KR20060019540A (en) | Topical composition for transdermal administration | |
| WO2013050959A1 (en) | Composition for the treatment of skin lesions | |
| CN106309156A (en) | Ferulic acid acne fading solution and preparation method thereof | |
| CN109731101A (en) | A kind of photosensitive medicament patch and preparation method | |
| KR101892079B1 (en) | Composition for improving acnes and kit for improving acnes containing the same | |
| CN103108640A (en) | Pharmaceutical or cosmetic composition containing nicotinic acid adenine dinucleotide phosphate or derivative thereof | |
| BR102018002462A2 (en) | kit, topical composition, film and its uses | |
| CN103385838A (en) | Anti-freckle whitening emulsion | |
| CN107233303A (en) | A kind of aminolevulinic acid cold cream and its preparation method and application | |
| CN109745262B (en) | Composition for whitening spot-fading face cream | |
| ES2214066T3 (en) | PREPARATION OF KHELLINA FOR THE TOPICAL THERAPY OF PSORIASIS, ITS SUBTIPOS, SPECIAL FORMS, AS WELL AS THE TOPIC THERAPY OF ECZEMAS. | |
| JP3712673B2 (en) | Gel composition and oil-in-water (O / W) type composition | |
| CN107519119A (en) | A kind of snake gall anti-acne essence cream and preparation method thereof | |
| RU2325900C2 (en) | Skin composition of external application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20171010 |
|
| RJ01 | Rejection of invention patent application after publication |